Results 21 to 30 of about 3,343,278 (165)

Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats

Neurobiology of Disease, 2020
Acetylcholine muscarinic receptors (mAChRs) contribute to both the facilitation and inhibition of levodopa-induced dyskinesia operated by striatal cholinergic interneurons, although the receptor subtypes involved remain elusive.
Alberto Brugnoli, Clarissa Anna Pisanò, Michele Morari   +2 more
doaj   +1 more source

Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia

Frontiers in Aging Neuroscience, 2022
BackgroundThe pathophysiology of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) is not well understood. Experimental data from numerous investigations support the idea that aberrant activity of D1 dopamine receptor-positive medium spiny ...
Shasha Gao, Rui Gao, Lu Yao, Jie Feng, Wanyuan Liu, Yingqiong Zhou, Qiongchi Zhang, Yong Wang, Jian Liu   +8 more
doaj   +1 more source

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia

Neurobiology of Disease, 2016
Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli, Francesco Napolitano, Alessandro Usiello, Michele Morari   +3 more
doaj   +1 more source

Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model

IBRO Reports, 2019
Parkinson's disease is a progressive debilitative neurodegenerative disease characterised mostly with bradykinesia, tremor, catatonia, drooping posture, unsteady gate and unstable steps.
Nazanin Aboulghasemi, Mahsa Hadipour Jahromy, Amir Ghasemi   +2 more
doaj   +1 more source

Slow wave activity across sleep-night could predict levodopa-induced dyskinesia. [PDF]

Sci Rep, 2023
A disruption in the slow wave activity (SWA) mediated synaptic downscaling process features Parkinson's disease (PD) patients presenting levodopa-induced dyskinesia (LID).
Amato N, Caverzasio S, Manconi M, Staedler C, Kaelin-Lang A, Galati S.   +5 more
europepmc   +3 more sources

The mitogenome mutation repertoire affects progression of Parkinson’s Disease [PDF]

Genetics and Molecular Biology
Mitochondrial genome variation is a risk factor for Parkinson’s disease, but its role in levodopa-induced dyskinesia remains incompletely understood. This study examines the mitochondrial mutation repertoire as a potential biomarker for levodopa-induced ...
Gustavo Barra Matos, Camille Sena dos Santos, Letícia Cota Cavaleiro de Macêdo, Juliana Paiva dos Santos Diniz, Tatiane Piedade de Sousa, Giovanna Chaves Cavalcante, Caio Santos Silva, Rebecca Lais da Silva Cruz, Dafne Dalledone Moura, Andrea Ribeiro-dos-Santos, Bruno Lopes Santos-Lobato, Gilderlanio Santana de Araújo   +11 more
doaj   +2 more sources

Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double‐Blind Primary Endpoint

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single‐center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects.
Alfons Schnitzler, Pablo Mir, Matthew A. Brodsky, Leonard Verhagen, Sergiu Groppa, Ramiro Alvarez, Andrew Evans, Marta Blazquez, Sean Nagel, Julie G. Pilitsis, Monika Pötter‐Nerger, Winona Tse, Leonardo Almeida, Nestor Tomycz, Joohi Jimenez‐Shahed, Witold Libionka, Fatima Carrillo, Christian J. Hartmann, Stefan Jun Groiss, Martin Glaser, Florence Defresne, Edward Karst, Binith Cheeran, Jan Vesper, for the PROGRESS Study Investigators   +24 more
wiley   +1 more source

Predictors of levo-dopa induced dyskinesias in Parkinson's disease

Annals of Indian Academy of Neurology, 2020
Background: Levodopa has a superior antiparkinsonian effect than dopamine agonists making it the standard of care for patients with Parkinson's disease (PD). During the initial stages, PD patients show a steady response to levodopa. Response fluctuations
R T Athulya, S Jayakrishnan, Thomas Iype, Reeja Rajan, Paul J Alapatt   +4 more
doaj   +1 more source

Deep Brain Stimulation of Caudal Zona Incerta for Parkinson's Disease: One‐Year Follow‐Up and Electric Field Simulations

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objective To evaluate the effects of bilateral caudal zona incerta (cZi) deep brain stimulation (DBS) for Parkinson's disease (PD) one year after surgery and to create anatomical improvement maps based on patient‐specific simulation of the electric field.
Rasmus Stenmark Persson, Teresa Nordin, Gun‐Marie Hariz, Karin Wårdell, Lars Forsgren, Marwan Hariz, Patric Blomstedt   +6 more
wiley   +1 more source

Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts. [PDF]

, 2018
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal ...
Calabresi, Paolo, Calabresi P., Morgante, Francesca, Marsili, Luca, Luca Marsili, Anthony E. Lang, Paolo Calabresi, Bezard, Erwan, Picconi, Barbara, Fasano, Alfonso, Lang, Anthony E., Picconi, B, Alberto J. Espay, Merola, A, Espay, Alberto J., Fasano, A, Espay, AJ, Marsili, L, Calabresi, P, Francesca Morgante, Morgante, F, Alfonso Fasano, Lang, AE, Susan H. Fox, Aristide Merola, Fox, SH, Barbara Picconi, Fox, Susan H., Merola A., Merola, Aristide, Bezard, E, Erwan Bezard, Fasano A.   +32 more
core   +1 more source